|
Full Prescribing Information:
https://data.health.gov.il/drugs/alonim/Rishum_11_504862219.pdf
Betmiga™ (mirabegron) 25 mg and 50 mg prolonged-release tablets are available on medical prescription only.
Any suspected adverse event associated with Betmiga 25 mg and 50 mg should be reported to the Ministry of Health according to the National Regulation by using an online form https://sideeffects.health.gov.il/
Adverse events may also be reported to Astellas Pharma International B.V Pharmacovigilance.IL@astellas.com
Further information available upon request from: Astellas Pharma International B.V., Israel
| 
